Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation.
In Japan, ABO-incompatible kidney transplantation has been performed in more than 1000 patients since 1989, and recently accounts for about 18% of all living donor kidney transplants. As for outcomes, since 2001 the 1-year and 3-year graft survival rates have increased to 96% and 94%, respectively, which are similar to those in ABO-compatible transplantation. These improved outcomes are attributed to a clearer understanding of the mechanisms underlying accommodation and acute antibody-mediated rejection, permitting the development of new therapeutic strategies. This review classifies and discusses the clinical significance of acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation.
Takahashi
Kota
K
Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata, Niigata, 951-8510, Japan. kota@med.niigata-u.ac.jp.
D001789:Blood Group Antigens / Q000502:physiology*; D001787:Blood Group Incompatibility; D006084:Graft Rejection / Q000145:classification / Q000276:immunology* / Q000628:therapy; D006085:Graft Survival / Q000276:immunology / Q000502:physiology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D015996:Survival Rate
D001789:Blood Group Antigens